Canopy Growth Bets On Europe As It Relaunches This Legacy Brand in Germany’s $1B Medical Cannabis Market

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) is relaunching the Tweed brand in Germany’s medical cannabis market.

The Canadian cannabis company also announced the launch of three premium strains from MTL Cannabis Corp., including Pablo’s Revenge, Dante’s Inferno, and Frost’d Flakes. Canopy said more strains are planned to reach shelves in the European country through 2026, with up to five MTL-derived strains expected to be introduced next month.

Canopy acquired MTL Cannabis earlier this year. That deal expanded premium flower supply for Canopy, enhanced operating execution and ability to meet demand in regulated international medical markets such as Europe.

According to a new report from the Global Cannabis Network Collective and Whitney Economics, Europe is a major factor in shaping the next phase of the global cannabis industry, as it holds the position of the world’s second-largest cannabis market by value.

The growth is driven by medical cannabis programs that amplify, as well as telemedicine adoption, international trade, and stricter EU/UK pharmaceutical manufacturing standards.

Luc Mongeau, CEO of Canopy Growth, recognizes the opportunity.

“We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” Mongeau said in a press release in which the company’s management cited Germany approaching a $1 billion annual medical cannabis market in 2025.

“Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly,” Mongeau continued. “The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care.”

Canopy’s third quarter report of fiscal 2026, which was revealed in February, showed roughly flat year-over-year revenue of CA$74.5 million ($54.3 million), a narrowed net loss year-over-year of 49%, and an adjusted EBITDA loss that narrowed by 17% year-over-year.

Canopy said previously that the integration of a profitable, cash-generating business, such as MTL Cannabis, “supports the Company’s objective of achieving positive adjusted EBITDA during fiscal 2027.”

The company is scheduled to report fourth-quarter and full-year fiscal 2026 results on June 15.

CGC Price Action

Canopy’s shares traded 1.30% lower at $1.52 per share at the time of writing on Friday.